Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

3(37.5%)

Phase 3

3(37.5%)

Phase 2

2(25.0%)

8Total

Phase 1(3)

Phase 3(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06887127Phase 3Recruiting

A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis

Role: lead

NCT06396026Phase 3Recruiting

A Study of Efficacy and Safety of TLL-018 in CSU Participants

Role: lead

NCT05772520Phase 2Completed

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Role: lead

NCT05373355Phase 1Completed

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

Role: lead

NCT05945810Phase 1Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Role: lead

NCT06020144Phase 3Unknown

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

Role: lead

NCT05342428Phase 1Completed

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

Role: lead

NCT05133297Phase 2Completed

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

Role: lead

All 8 trials loaded